论文部分内容阅读
目的探讨HER-2与CD44v6表达与乳腺癌的关系,为患者判断预后及选择治疗方案提供参考依据。方法筛选近2年乳腺癌根治标本100例,进行免疫组织化学标记并分析。结果CD44v6的阳性率为81%(81/100);HER-2的阳性率为74%(74/100);CD44v6表达与患者年龄、肿瘤大小、TNM分期差异无统计学意义(P>0.05),与腋淋巴结转移情况及组织学类型相关(P<0.05),HER-2的阳性表达与患者年龄、肿瘤大小、TNM分期差异无统计学意义(P>0.05),而与腋淋巴结转移相关。结论CD44v6和HER-2与腋淋巴结转移情况相关,CD44v6与组织学类型有关,均可作为判断乳腺癌预后的参考指标。
Objective To investigate the relationship between the expression of HER-2 and CD44v6 and breast cancer, and provide reference for patients’ prognosis and selection of treatment plan. Methods A total of 100 cases of radical mastectomy in the past 2 years were screened for immunohistochemistry and analyzed. Results The positive rate of CD44v6 was 81% (81/100); the positive rate of HER-2 was 74% (74/100); there was no significant difference in CD44v6 expression with age, tumor size, and TNM stage (P>0.05). There was a correlation between lymph node metastasis and histological types (P<0.05). There was no significant difference in the positive expression of HER-2 with age, tumor size, TNM stage (P>0.05), and it was related to axillary lymph node metastasis. Conclusions CD44v6 and HER-2 are associated with axillary lymph node metastasis. CD44v6 is associated with histological type and can be used as a reference index for judging the prognosis of breast cancer.